Cargando…
Nicotine Population Pharmacokinetics in Healthy Adult Smokers: A Retrospective Analysis
BACKGROUND AND OBJECTIVE: Characterizing nicotine pharmacokinetics is challenging in the presence of background exposure. We performed a combined retrospective population pharmacokinetic analysis of 8 trials, including exposure to Tobacco Heating System and cigarettes (both inhaled), nicotine nasal...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5681983/ https://www.ncbi.nlm.nih.gov/pubmed/28283988 http://dx.doi.org/10.1007/s13318-017-0405-2 |
_version_ | 1783278016806256640 |
---|---|
author | Marchand, Mathilde Brossard, Patrick Merdjan, Henri Lama, Nicola Weitkunat, Rolf Lüdicke, Frank |
author_facet | Marchand, Mathilde Brossard, Patrick Merdjan, Henri Lama, Nicola Weitkunat, Rolf Lüdicke, Frank |
author_sort | Marchand, Mathilde |
collection | PubMed |
description | BACKGROUND AND OBJECTIVE: Characterizing nicotine pharmacokinetics is challenging in the presence of background exposure. We performed a combined retrospective population pharmacokinetic analysis of 8 trials, including exposure to Tobacco Heating System and cigarettes (both inhaled), nicotine nasal spray and oral nicotine gum. METHOD: Data from 4 single product use trials were used to develop a population pharmacokinetic model with Phoenix(®) NLME™ and to derive exposure parameters. Data from 4 separate ad libitum use studies were used for external validation. A total of 702 healthy adult smokers (54% males; 21–66 years of age; smoking ≥10 cigarettes/day; from US, Europe and Japan) were eligible for participation. RESULTS: Two-compartment linear disposition combined with zero-order absorption model was adequate to describe nicotine pharmacokinetics, and a mono-exponentially decreasing background component was utilized to account for nicotine carry-over effects. Apparent nicotine clearance was typically 0.407 L/min in males and 26% higher in females (68% inter-individual variability). Bioavailability was product-specific, decreased with increasing nicotine ISO yield, and increased with increasing body weight. Absorption duration was apparently prolonged with nicotine gum. The typical initial and terminal half-lives were 1.35 and 17 h, respectively. The presence of menthol did not impact the determinants of the area under the curve. The model adequately described the external validation data. CONCLUSIONS: The population model was able to describe in different populations the nicotine pharmacokinetics after single product use and after 4 days of ad libitum use of Tobacco Heating System, cigarettes, and of different nicotine replacement therapies with various routes of administration. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s13318-017-0405-2) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5681983 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-56819832017-11-22 Nicotine Population Pharmacokinetics in Healthy Adult Smokers: A Retrospective Analysis Marchand, Mathilde Brossard, Patrick Merdjan, Henri Lama, Nicola Weitkunat, Rolf Lüdicke, Frank Eur J Drug Metab Pharmacokinet Original Research Article BACKGROUND AND OBJECTIVE: Characterizing nicotine pharmacokinetics is challenging in the presence of background exposure. We performed a combined retrospective population pharmacokinetic analysis of 8 trials, including exposure to Tobacco Heating System and cigarettes (both inhaled), nicotine nasal spray and oral nicotine gum. METHOD: Data from 4 single product use trials were used to develop a population pharmacokinetic model with Phoenix(®) NLME™ and to derive exposure parameters. Data from 4 separate ad libitum use studies were used for external validation. A total of 702 healthy adult smokers (54% males; 21–66 years of age; smoking ≥10 cigarettes/day; from US, Europe and Japan) were eligible for participation. RESULTS: Two-compartment linear disposition combined with zero-order absorption model was adequate to describe nicotine pharmacokinetics, and a mono-exponentially decreasing background component was utilized to account for nicotine carry-over effects. Apparent nicotine clearance was typically 0.407 L/min in males and 26% higher in females (68% inter-individual variability). Bioavailability was product-specific, decreased with increasing nicotine ISO yield, and increased with increasing body weight. Absorption duration was apparently prolonged with nicotine gum. The typical initial and terminal half-lives were 1.35 and 17 h, respectively. The presence of menthol did not impact the determinants of the area under the curve. The model adequately described the external validation data. CONCLUSIONS: The population model was able to describe in different populations the nicotine pharmacokinetics after single product use and after 4 days of ad libitum use of Tobacco Heating System, cigarettes, and of different nicotine replacement therapies with various routes of administration. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s13318-017-0405-2) contains supplementary material, which is available to authorized users. Springer International Publishing 2017-03-10 2017 /pmc/articles/PMC5681983/ /pubmed/28283988 http://dx.doi.org/10.1007/s13318-017-0405-2 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Research Article Marchand, Mathilde Brossard, Patrick Merdjan, Henri Lama, Nicola Weitkunat, Rolf Lüdicke, Frank Nicotine Population Pharmacokinetics in Healthy Adult Smokers: A Retrospective Analysis |
title | Nicotine Population Pharmacokinetics in Healthy Adult Smokers: A Retrospective Analysis |
title_full | Nicotine Population Pharmacokinetics in Healthy Adult Smokers: A Retrospective Analysis |
title_fullStr | Nicotine Population Pharmacokinetics in Healthy Adult Smokers: A Retrospective Analysis |
title_full_unstemmed | Nicotine Population Pharmacokinetics in Healthy Adult Smokers: A Retrospective Analysis |
title_short | Nicotine Population Pharmacokinetics in Healthy Adult Smokers: A Retrospective Analysis |
title_sort | nicotine population pharmacokinetics in healthy adult smokers: a retrospective analysis |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5681983/ https://www.ncbi.nlm.nih.gov/pubmed/28283988 http://dx.doi.org/10.1007/s13318-017-0405-2 |
work_keys_str_mv | AT marchandmathilde nicotinepopulationpharmacokineticsinhealthyadultsmokersaretrospectiveanalysis AT brossardpatrick nicotinepopulationpharmacokineticsinhealthyadultsmokersaretrospectiveanalysis AT merdjanhenri nicotinepopulationpharmacokineticsinhealthyadultsmokersaretrospectiveanalysis AT lamanicola nicotinepopulationpharmacokineticsinhealthyadultsmokersaretrospectiveanalysis AT weitkunatrolf nicotinepopulationpharmacokineticsinhealthyadultsmokersaretrospectiveanalysis AT ludickefrank nicotinepopulationpharmacokineticsinhealthyadultsmokersaretrospectiveanalysis |